Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)
BackgroundCladribine tablets (marketed as Mavenclad) are a new oral therapy, which has recently been listed on the pharmaceutical benefits scheme in Australia for the treatment of relapsing multiple sclerosis (MS). The current dosing schedule is for 2 courses given a year apa...
Main Authors: | Vicki E Maltby, Rodney A Lea, Mastura Monif, Marzena J Fabis-Pedrini, Katherine Buzzard, Tomas Kalincik, Allan G Kermode, Bruce Taylor, Suzanne Hodgkinson, Pamela McCombe, Helmut Butzkueven, Michael Barnett, Jeannette Lechner-Scott |
---|---|
Format: | Article |
Language: | English |
Published: |
JMIR Publications
2021-10-01
|
Series: | JMIR Research Protocols |
Online Access: | https://www.researchprotocols.org/2021/10/e24969 |
Similar Items
-
Immunomodulatory Effects Associated with Cladribine Treatment
by: Nicolás Fissolo, et al.
Published: (2021-12-01) -
Response to cladribine in patient with systemic mastocytosis
by: Radojković Milica, et al.
Published: (2011-01-01) -
Cladribine tablets after treatment with natalizumab (CLADRINA) – rationale and design
by: Peter V. Sguigna, et al.
Published: (2024-04-01) -
Efficacy and toxicity of cladribine for the treatment of refractory acute myeloid leukemia: a meta-analysis
by: Zhou A, et al.
Published: (2019-05-01) -
EFFICACY AND SAFETY OF CLADRIBINE: SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION IN HAIRY CELL LEUKEMIA PATIENTS
by: Ola Khorshid, et al.
Published: (2015-10-01)